Literature DB >> 23139599

Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease.

Matteo Nicola Dario Di Minno1, Anna Russolillo, Roberta Lupoli, Pasquale Ambrosino, Alessandro Di Minno, Giovanni Tarantino.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) has been recognized as a major health burden. It is the most important cause of chronic liver disease and a major independent cardiovascular risk factor. Lacking a definite treatment for NAFLD, a specific diet and an increase in physical activity represent the most commonly used therapeutic approaches. In this review, major literature data about the use of omega-3 polyunsaturated fatty acids (n-3 PUFAs) as a potential treatment of NAFLD have been described. n-3 PUFAs, besides having a beneficial impact on most of the cardio-metabolic risk factors (hypertension, hyperlipidemia, endothelial dysfunction and atherosclerosis) by regulating gene transcription factors [i.e., peroxisome proliferator-activated receptor (PPAR) α, PPARγ, sterol regulatory element-binding protein-1, carbohydrate responsive element-binding protein], impacts both lipid metabolism and on insulin sensitivity. In addition to an enhancement of hepatic beta oxidation and a decrease of the endogenous lipid production, n-3 PUFAs are able to determine a significant reduction of the expression of pro-inflammatory molecules (tumor necrosis factor-α and interleukin-6) and of oxygen reactive species. Further strengthening the results of the in vitro studies, both animal models and human intervention trials, showed a beneficial effect of n-3 PUFAs on the severity of NAFLD as expressed by laboratory parameters and imaging measurements. Despite available results provided encouraging data about the efficacy of n-3 PUFAs as a treatment of NAFLD in humans, well-designed randomized controlled trials of adequate size and duration, with histological endpoints, are needed to assess the long-term safety and efficacy of PUFA, as well as other therapies, for the treatment of NAFLD and non-alcoholic steatohepatitis patients. It is worthwhile to consider that n-3 PUFAs cannot be synthesized by the human body and must be derived from exogenous sources (fish oil, flaxseeds, olive oil) which are typical foods of the Mediterranean diet, known for its beneficial effects in preventing obesity, diabetes and, in turn, cardiovascular events. According to these data, it is important to consider that most of the beneficial effects of n-3 PUFAs can also be obtained by an equilibrate nutrition program.

Entities:  

Keywords:  Animal models; Hepatic steatosis; Non-alcoholic fatty liver disease; Omega-3 polyunsaturated fatty acids

Mesh:

Substances:

Year:  2012        PMID: 23139599      PMCID: PMC3491590          DOI: 10.3748/wjg.v18.i41.5839

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  83 in total

1.  Changes in tissue lipids and tissue histology resulting from essential fatty acid deficiency in rats.

Authors:  R B ALFIN-SLATER; S BERNICK
Journal:  Am J Clin Nutr       Date:  1958 Nov-Dec       Impact factor: 7.045

2.  High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism.

Authors:  Matteo Nicola Dario Di Minno; Antonella Tufano; Anna Rusolillo; Giovanni Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

3.  Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population.

Authors:  Maria Stepanova; Zobair M Younossi
Journal:  Clin Gastroenterol Hepatol       Date:  2012-01-13       Impact factor: 11.382

4.  Effect of diet on lipid metabolism in experimental animals and man.

Authors:  R H Herman; D Zakim; F B Stifel
Journal:  Fed Proc       Date:  1970 May-Jun

5.  Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial.

Authors:  Valerio Nobili; Giorgio Bedogni; Anna Alisi; Andrea Pietrobattista; Patrizia Risé; Claudio Galli; Carlo Agostoni
Journal:  Arch Dis Child       Date:  2011-01-12       Impact factor: 3.791

Review 6.  International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.

Authors:  Liliane Michalik; Johan Auwerx; Joel P Berger; V Krishna Chatterjee; Christopher K Glass; Frank J Gonzalez; Paul A Grimaldi; Takashi Kadowaki; Mitchell A Lazar; Stephen O'Rahilly; Colin N A Palmer; Jorge Plutzky; Janardan K Reddy; Bruce M Spiegelman; Bart Staels; Walter Wahli
Journal:  Pharmacol Rev       Date:  2006-12       Impact factor: 25.468

Review 7.  Exploring newer cardioprotective strategies: ω-3 fatty acids in perspective.

Authors:  Matteo Nicola Dario Di Minno; Elena Tremoli; Antonella Tufano; Anna Russolillo; Roberta Lupoli; Giovanni Di Minno
Journal:  Thromb Haemost       Date:  2010-08-30       Impact factor: 5.249

Review 8.  Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.

Authors:  P Pettinelli; A M Obregón; L A Videla
Journal:  Nutr Hosp       Date:  2011 May-Jun       Impact factor: 1.057

9.  Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent.

Authors:  Laura H Tetri; Metin Basaranoglu; Elizabeth M Brunt; Lisa M Yerian; Brent A Neuschwander-Tetri
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09-04       Impact factor: 4.052

10.  Hepatic n-3 polyunsaturated fatty acid depletion promotes steatosis and insulin resistance in mice: genomic analysis of cellular targets.

Authors:  Barbara D Pachikian; Ahmed Essaghir; Jean-Baptiste Demoulin; Audrey M Neyrinck; Emilie Catry; Fabienne C De Backer; Nicolas Dejeans; Evelyne M Dewulf; Florence M Sohet; Laurence Portois; Louise Deldicque; Olivier Molendi-Coste; Isabelle A Leclercq; Marc Francaux; Yvon A Carpentier; Fabienne Foufelle; Giulio G Muccioli; Patrice D Cani; Nathalie M Delzenne
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

View more
  47 in total

1.  Lowering the dietary omega-6: omega-3 does not hinder nonalcoholic fatty-liver disease development in a murine model.

Authors:  Reilly T Enos; Kandy T Velázquez; Jamie L McClellan; Taryn L Cranford; Michael D Walla; E Angela Murphy
Journal:  Nutr Res       Date:  2015-04-11       Impact factor: 3.315

Review 2.  Targeting inflammation in diabetes: Newer therapeutic options.

Authors:  Neeraj Kumar Agrawal; Saket Kant
Journal:  World J Diabetes       Date:  2014-10-15

3.  Dietary patterns are associated with prevalence of fatty liver disease in adults.

Authors:  Q Jia; Y Xia; Q Zhang; H Wu; H Du; L Liu; C Wang; H Shi; X Guo; X Liu; C Li; S Sun; X Wang; H Zhao; K Song; G Huang; Y Wu; N Cui; K Niu
Journal:  Eur J Clin Nutr       Date:  2015-02-04       Impact factor: 4.016

4.  Linoleic and α-linolenic fatty acid consumption over three generations exert cumulative regulation of hepatic expression of genes related to lipid metabolism.

Authors:  Carolina B Jacometo; Eduardo Schmitt; Luiz F M Pfeifer; Augusto Schneider; Francielle Bado; Fernanda T da Rosa; Simone Halfen; Francisco A B Del Pino; Juan J Loor; Marcio N Corrêa; Nelson J L Dionello
Journal:  Genes Nutr       Date:  2014-05-20       Impact factor: 5.523

Review 5.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

Review 6.  Modulation of hepatic steatosis by dietary fatty acids.

Authors:  Alessandra Ferramosca; Vincenzo Zara
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 7.  Non-alcoholic fatty liver disease: a diabetologist's perspective.

Authors:  Joseph M Pappachan; Farrah A Antonio; Mahamood Edavalath; Arjun Mukherjee
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

Review 8.  Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet.

Authors:  Ludovico Abenavoli; Natasa Milic; Valentina Peta; Francesco Alfieri; Antonino De Lorenzo; Stefano Bellentani
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

9.  Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice.

Authors:  Donald B Jump; Christopher M Depner; Sasmita Tripathy; Kelli A Lytle
Journal:  Proc Nutr Soc       Date:  2015-08-18       Impact factor: 6.297

Review 10.  Nutrition, nonalcoholic fatty liver disease and the microbiome: recent progress in the field.

Authors:  Miriam B Vos
Journal:  Curr Opin Lipidol       Date:  2014-02       Impact factor: 4.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.